Local reactions from subcutaneous allergen immunotherapy

Immunotherapy

Volumn 5, Issue 12, 2013, Pages 1339-1345

  Coop, Christopher A ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

allergen immunotherapy; local reactions; systemic reactions

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; ANTIHISTAMINIC AGENT; BEE VENOM; FEXOFENADINE; GLYCEROL; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHORYL LIPID A; RANITIDINE; TERFENADINE;

ARTICLE; DISEASE ASSOCIATION; HOSPITAL POLICY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SKIN MANIFESTATION; SUBCUTANEOUS IMMUNOTHERAPY; TREATMENT OUTCOME; TREATMENT REFUSAL;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; SKIN DISEASES; T-LYMPHOCYTES;

EID: 84889600330     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.143     Document Type: Article

References (46)

1. Bousquet J, Lockey RF, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 53, 1-42 (1998) (Pubitemid 28346358)
2. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann. Allergy 56, 331-334 (1986) (Pubitemid 16102118)
3. Prigal SJ. A ten-year study of repository injections of allergens: local reactions and their management. Ann. Allergy 30, 529-535 (1972)
4. Nicklas RA, Bernstein I, Blessing-Moore J et al. Practice parameters for allergen immunotherapy. J. Allergy Clin. Immunol. 98, 1001-1011 (1996) (Pubitemid 27014789)
5. Schoenwetter WF. Safe allergen immunotherapy: the correct allergen, the appropriate patient, the adequate dose. Postgrad. Med. 100, 123-126, 131-135 (1996)
6. Grammer LC, Greenberger PA. Patterson's Allergic Diseases (7th Edition) Lippincott Williams & Wilkins, MD, USA, 192 (2009)
7. Wright DN, Lockey RF. Local reactions to stinging insects (Hymenoptera) Allergy Proc. 11, 23-28 (1990)
8. Epstein TG, Liss GM, Murphy-Berendts K et al. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Ann. Allergy Asthma Immunol. 107, 426-431 (2011)
9. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J. Allergy Clin. Immunol. 123, 493-498 (2009)
10. Passalacqua G, Baena-Cagnani CE, Bousquet J et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J. Allergy Clin. Immunol. 32, 93-98 (2013)
11. Roger A, Justicia JL, Navarro LA et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int. Arch. Allergy Immunol. 154, 69-75 (2011)
12. Solley GO, Gleich GL, Jordan RE et al. Late phase of the immediate wheal and flare skin reactions: its dependence on IgE antibodies. J. Clin. Invest. 58, 408-420 (1976)
13. Dolovich J, Hargreave FE, Chalmers R et al. Late cutaneous allergic responses in isolated IgE-dependent reactions. J. Allergy Clin. Immunol. 52, 38-46 (1973)
14. Smith KJ, Skelton HG, Ruiz N et al. Cutaneous reactions at the site of post-infection gp160 vaccination therapy in HIV1+ patients. Int. J. Dermatol. 37, 293-298 (1998) (Pubitemid 28189694)
15. Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am. J. Med. 68, 479-485 (1980) (Pubitemid 10141810)
16. Stein MR, Brown Gl, Lima JE et al. A laboratory evaluation of immune complexes in patients on inhalant immunotherapy. J. Allergy Clin. Immunol. 62, 211-216 (1978) (Pubitemid 9032668)
17. Levinson AI, Summer RJ, Lawley TJ et al. Evaluation of the adverse effects of long-term hyposensitization. J. Allergy Clin. Immunol. 62, 109-114 (1978) (Pubitemid 9003163)
18. Nelson HS. The effect of preservatives and conditions of storage on the potency of allergy extract. J. Allergy Clin. Immunol. 67, 64-69 (1981) (Pubitemid 11155095)
19. Van Metre TE, Rosenberg GL, Vaswani SK et al. Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. J. Allergy Clin. Immunol. 97, 1033-1039 (1996) (Pubitemid 26154199)
20. D'Amato G, Kordash TR, Liccardi G et al. Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study. Clin. Exp. Allergy 25, 149-158 (1995)
21. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497-505 (2004) (Pubitemid 39421059)
22. Ozden MG, Kefeli M, Aydin F et al. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma. J. Cutan. Pathol. 36(7), 812-814 (2009)
23. Avcin S, Jazbec J, Jancar J. Subcutaneous nodule after vaccination with an aluminum-containing vaccine. Acta Dermatovenerol. Alp. Panonica Adriat. 17, 182-184 (2008)
24. Casanovas M, Martín R, Jiménez C et al. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int. Arch. Allergy Immunol. 139, 153-158 (2006) (Pubitemid 43177328)
25. Tankersley MS, Butler KK, Butler WK et al. Local reactions during allergen immunotherapy do not require dose adjustment. J. Allergy Clin. Immunol. 106, 840-843 (2000)
26. Belshe RB, Leone PA, Bernstein DI et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366, 34-43 (2012)
27. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy Ann. Intern. Med. 92, 620-624 (1980) (Pubitemid 10107551)
28. Can D, Demir E, Tanac R, Gulen F, Yenigun A. Immediate adverse reactions to immunotherapy. J. Investig. Allergol. Clin. Immunol. 13, 177-178 (2003)
29. Coop, CA, Tankersley MS. Are local reactions from allergen immunotherapy injections worrisome to patients? Ann. Allergy Asthma Immunol. 101, 96-100 (2008) (Pubitemid 352000751)
30. Ramirez DA, Londono S, Evans R 3rd. Adverse reactions to venom immunotherapy. Ann. Allergy 47, 435-439 (1981) (Pubitemid 12203224)
31. Coop CA, Tankersley MS. Dose adjustment practices among allergists for local reactions from immunotherapy. Ann. Allergy Asthma Immunol. 99, 77-81 (2007) (Pubitemid 47075955)
32. Hepner MJ, Ownby DR, MacKechnie H et al. The safety of immunotherapy -a prospective study. J. Allergy Clin. Immunol. 79, 133 (1987)
33. Portnoy J, Bagstad K, Kanarek H et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann. Allergy 73, 409-418 (1994) (Pubitemid 24368195)
34. Tankersley MS. Local reactions during allergen immunotherapy do not require dose adjustment: data over 3 years from a solo practice. Ann. Allergy Asthma Immunol. 90, 100 (2003)
35. Tankersley MS. Dose adjustments are unnecessary for local reactions at immunotherapy satellite clinics. J. Allergy Clin. Immunol. 113, S111 (2004)
36. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether of not the dose is reduced after a local reaction. Ann. Allergy Asthma Immunol. 92, 225-227 (2004) (Pubitemid 38233660)
37. Calabria CW, Coop CA, Tankersley MS The LOCAL study: local reactions do not predict local reactions in allergen immunotherapy. J. Allergy Clin. Immunol. 124, 739-744 (2009)
38. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann. Allergy Asthma Immunol. 88, 391-394 (2002) (Pubitemid 34408565)
39. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J. Allergy Clin. Immunol. 91, 734-737 (1993) (Pubitemid 23110718)
40. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergy immunotherapy. Ann. Allergy Asthma Immunol. 82, 281-286 (1999) (Pubitemid 29141089)
41. Berchtold E, Maibach R, Muller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin. Exp. Allergy 22, 59-65 (1992)
42. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 100, 458-463 (1997)
43. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55, 484-488 (2000) (Pubitemid 30230359)
44. Alessandrini AE, Berra D, Rizzini FL et al. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann. Allergy Asthma Immunol. 97, 92-97 (2006) (Pubitemid 44156344)
45. Jackson LA, Dunstan M, Starkovich P et al. Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria-tetanus toxoids-acellular pertussis vaccination: a randomized, controlled trial. Pediatrics 117, 620-625 (2006) (Pubitemid 46063201)
46. Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ 333, 571-577 (2006)